CIK 0001662579
- Non-accelerated filer
- Smaller reporting company
C4 Therapeutics, Inc.
Sign in to watch- Ticker
- CCCC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 475617627
- Phone
- +1 617-231-0700
- Business address
- 490 ARSENAL WAY, SUITE 120, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $122,487
- in 1 filing, $122K under 10b5-1 plans
Net −$122,487. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-20 | DOWNEY BRUCE Director | Grant or award · Stock Option (Right to Buy) | +32,500 | 32,500 | ||
| 2023-06-15 | DOWNEY BRUCE Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2022-06-22 | DOWNEY BRUCE Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2021-06-15 | DOWNEY BRUCE Director | Grant or award · Stock Option (Right to Buy) | +23,500 | 23,500 | ||
| 2020-10-06 | DOWNEY BRUCE Director | Conversion | +237,148 | 237,148 | ||
| 2020-10-06 | DOWNEY BRUCE Director | Conversion | +252,394 | 489,542 | ||
| 2020-10-06 | DOWNEY BRUCE Director | Conversion · Series A Preferred Stock | −2,000,000 | 0 | ||
| 2020-10-06 | DOWNEY BRUCE Director | Conversion · Series B Preferred Stock | −2,128,571 | 0 | ||
| 2020-10-01 | DOWNEY BRUCE Director | Grant or award · Stock Option (Right to Buy) | +17,786 | 17,786 |
Page 1 of 1 · 9 trades